LEXINGTON, Mass. & SYDNEY--(BUSINESS WIRE)--GI Dynamics, Inc. (ASX: GID) announced new data results that reveal changes in certain hormones in patients treated with the EndoBarrier® Gastrointestinal Liner (the EndoBarrier), which results in rapid improvement in glycemic control and weight loss. These data were presented during an oral session at the 47th Annual Meeting of the European Association for the Study of Diabetes and Obesity (EASD).
